Natalie Matosin1, Francesca Fernandez-Enright2, Elisabeth Frank1, Chao Deng1, Jenny Wong3, Xu-Feng Huang1, Kelly A Newell1. 1. The Faculty of Science, Medicine and Health, University of Wollongong, New South Wales, Illawarra Health and Medical Research Institute, Wollongong, New South Wales, and Schizophrenia Research Institute, Sydney, New South Wales, Australia. 2. The Faculty of Science, Medicine and Health, University of Wollongong, New South Wales, Illawarra Health and Medical Research Institute, Wollongong, New South Wales, Schizophrenia Research Institute, Sydney, New South Wales, and School of Psychology, Faculty of Social Science, University of Wollongong, New South Wales, Australia. 3. The Faculty of Science, Medicine and Health, University of Wollongong, New South Wales, and Illawarra Health and Medical Research Institute, Wollongong, New South Wales, Australia.
Abstract
BACKGROUND: Metabotropic glutamate receptors 2/3 (mGluR2/3) and 5 (mGluR5) are novel therapeutic targets for major depression (MD), bipolar disorder (BD) and schizophrenia. We aimed to determine whether mGluR2/3 and mGluR5 binding in the anterior cingulate cortex (ACC), a brain region essential for the regulation of mood, cognition and emotion, were differentially altered in these pathologies. METHODS: Using postmortem human brains derived from 2 cohorts, [(3)H]LY341495 binding to mGluR2/3 and [(3)H]MPEP binding to mGluR5 were measured by receptor autoradiography in the ACC. The first cohort comprised samples from individuals who had MD with psychosis (MDP), MD without psychosis (MDNP) and matched controls (n = 11-12 per group). The second cohort comprised samples from individuals who had MDNP, BD, schizophrenia and matched controls (n = 15 per group). RESULTS: No differences in mGluR2/3 or mGluR5 binding were observed in the MDP, MDNP, BD or schizophrenia groups compared with the control group (all p > 0.05). Importantly, there were also no differences in binding densities between the psychiatric disorders (p > 0.05). We did, however, observe age-related effects, with consistent negative associations between mGluR2/3 and age in the control group (r < -0.575, p < 0.025) and the psychotic disorder groups (MDP and schizophrenia: r = -0.765 to -0.515, p < 0.05), but not in the mood disorder groups (MDNP, BD). LIMITATIONS: Replication in larger independent cohorts and medication-naive individuals would strengthen these findings. CONCLUSION: Our findings suggest that mGluRs are unaltered in the ACC; however, the presence of altered receptor function cannot be discounted and requires further investigation. Taken together with previous studies, which report differential changes in mGluR2, 3 and 5 across these disorders, we suggest mGluRs may be affected in a brain region-specific manner.
BACKGROUND:Metabotropic glutamate receptors 2/3 (mGluR2/3) and 5 (mGluR5) are novel therapeutic targets for major depression (MD), bipolar disorder (BD) and schizophrenia. We aimed to determine whether mGluR2/3 and mGluR5 binding in the anterior cingulate cortex (ACC), a brain region essential for the regulation of mood, cognition and emotion, were differentially altered in these pathologies. METHODS: Using postmortem human brains derived from 2 cohorts, [(3)H]LY341495 binding to mGluR2/3 and [(3)H]MPEP binding to mGluR5 were measured by receptor autoradiography in the ACC. The first cohort comprised samples from individuals who had MD with psychosis (MDP), MD without psychosis (MDNP) and matched controls (n = 11-12 per group). The second cohort comprised samples from individuals who had MDNP, BD, schizophrenia and matched controls (n = 15 per group). RESULTS: No differences in mGluR2/3 or mGluR5 binding were observed in the MDP, MDNP, BD or schizophrenia groups compared with the control group (all p > 0.05). Importantly, there were also no differences in binding densities between the psychiatric disorders (p > 0.05). We did, however, observe age-related effects, with consistent negative associations between mGluR2/3 and age in the control group (r < -0.575, p < 0.025) and the psychotic disorder groups (MDP and schizophrenia: r = -0.765 to -0.515, p < 0.05), but not in the mood disorder groups (MDNP, BD). LIMITATIONS: Replication in larger independent cohorts and medication-naive individuals would strengthen these findings. CONCLUSION: Our findings suggest that mGluRs are unaltered in the ACC; however, the presence of altered receptor function cannot be discounted and requires further investigation. Taken together with previous studies, which report differential changes in mGluR2, 3 and 5 across these disorders, we suggest mGluRs may be affected in a brain region-specific manner.
Authors: Jukka Kupila; Olli Kärkkäinen; Virpi Laukkanen; Erkki Tupala; Jari Tiihonen; Markus Storvik Journal: Psychiatry Res Date: 2012-11-11 Impact factor: 3.222
Authors: W Liu; A C M Downing; L M Munsie; P Chen; M R Reed; C L Ruble; K T Landschulz; B J Kinon; L K Nisenbaum Journal: Pharmacogenomics J Date: 2010-12-21 Impact factor: 3.550
Authors: Marcus W Meinhardt; Anita C Hansson; Stephanie Perreau-Lenz; Christina Bauder-Wenz; Oliver Stählin; Markus Heilig; Clive Harper; Karla U Drescher; Rainer Spanagel; Wolfgang H Sommer Journal: J Neurosci Date: 2013-02-13 Impact factor: 6.167
Authors: D Martins-de-Souza; P C Guest; L W Harris; N Vanattou-Saifoudine; M J Webster; H Rahmoune; S Bahn Journal: Transl Psychiatry Date: 2012-03-13 Impact factor: 6.222
Authors: Martin Engel; Peta Snikeris; Natalie Matosin; Kelly Anne Newell; Xu-Feng Huang; Elisabeth Frank Journal: Psychopharmacology (Berl) Date: 2016-02-10 Impact factor: 4.530
Authors: Rocco D Gogliotti; Anna L Blobaum; Ryan M Morrison; J Scott Daniels; James M Salovich; Yiu-Yin Cheung; Alice L Rodriguez; Matthew T Loch; P Jeffrey Conn; Craig W Lindsley; Colleen M Niswender; Corey R Hopkins Journal: Bioorg Med Chem Lett Date: 2016-05-11 Impact factor: 2.823
Authors: Chadi G Abdallah; Jonas Hannestad; Graeme F Mason; Sophie E Holmes; Nicole DellaGioia; Gerard Sanacora; Lihong Jiang; David Matuskey; Ritvij Satodiya; Fabrizio Gasparini; Xin Lin; Jonathan Javitch; Beata Planeta; Nabeel Nabulsi; Richard E Carson; Irina Esterlis Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2017-04-06